90347-66-3

Basic information

• Product Name: METHYL 3-IODO-4-METHYLBENZOATE
• Synonyms: 3-IODO-4-METHYLBENZOIC ACID METHYL ESTER;METHYL 3-IODO-4-METHYLBENZOATE;METHYL 3-IODO-4-METH;2-Iodo-4-(methoxycarbonyl)toluene, Methyl 3-iodo-p-toluate
• CAS NO: 90347-66-3
• Molecular Formula: C₉H₉IO₂
• Molecular Weight: 276.07
• Product Categories: Aromatic Esters;Miscellaneous;Acids & Esters;Iodine Compounds;Benzenes
• Mol File: 90347-66-3.mol

Chemical Properties

• Melting Point: 93-95
• Boiling Point: 302.9 °C at 760 mmHg
• Flash Point: 137 °C
• Appearance: /
• Density: 1.666g/cm³
• Vapor Pressure: 0.000961mmHg at 25°C
• Refractive Index: 1.5975
• Storage Temp.: 2-8°C(protect from light)
• Water Solubility: Not miscible or difficult to mix with water.
• Sensitive: Light Sensitive
• CAS DataBase Reference: METHYL 3-IODO-4-METHYLBENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 3-IODO-4-METHYLBENZOATE(90347-66-3)
• EPA Substance Registry System: METHYL 3-IODO-4-METHYLBENZOATE(90347-66-3)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 90347-66-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
METHYL 3-IODO-4-METHYLBENZOATE is used as a reagent in the synthesis of [(pyrazolo[1,5-a]pyridmidinyl)ethynyl]benzamides, which are selective discoidin domain receptor 1 (DDR1) inhibitors. These inhibitors play a crucial role in the development of targeted therapies for various diseases, including cancer, by modulating the activity of DDR1, a receptor tyrosine kinase involved in cell adhesion, migration, and proliferation.
METHYL 3-IODO-4-METHYLBENZOATE is also used as a reagent in the preparation of orally bioavailable GZD824, a compound that targets the Breakpoint Cluster Region-Abelson (Bcr-Abl) kinase. This kinase is implicated in the development of chronic myeloid leukemia (CML) and other malignancies. GZD824 has the potential to overcome antitumor drug resistance, making it a promising candidate for the treatment of CML and other Abl-dependent cancers.

InChI:InChI=1/C9H9IO2/c1-6-3-4-7(5-8(6)10)9(11)12-2/h3-5H,1-2H3

Upstream product

• 67-56-1 methanol 
• 82998-57-0 3-iodo-4-toluic acid 
• 186581-53-3 diazomethane 
• 144-55-8 sodium hydrogencarbonate 
• 18595-18-1 3-amino-4-methyl benzoic acid methyl ester 

Downstream Products

• 229028-10-8 methyl 4-(bromomethyl)-3-iodo-benzoate 
• 272130-53-7 3-(3-hydroxy-prop-1-ynyl)-4-methyl-benzoic acid methyl ester 
• 876189-18-3 [5-(methoxycarbonyl)-2-methylphenyl]boronic acid 
• 272130-55-9 3-(3-bromo-propyl)-4-methyl-benzoic acid methyl ester 
• 165801-58-1 3-[3-(8-hydroxy-7,8-dihydro-6H-imidazo[4,5-d][1,3]diazepin-3-yl)-propyl]-4-methyl-benzoic acid methyl ester 
• 1027396-72-0 4-methyl-3-[3-(8-oxo-7,8-dihydro-6H-imidazo[4,5-d][1,3]diazepin-3-yl)-propyl]-benzoic acid methyl ester 
• 82998-57-0 3-iodo-4-toluic acid 
• 1191428-54-2 methyl 4-methyl-3-vinylbenzoate 
• 1021535-52-3 3-allyl-4-methyl-benzoic acid methyl ester 
• 23038-60-0 methyl 3-formyl-4-methyl-benzoate 
• 35066-28-5 methyl 3-acetyl-4-methylbenzoate 
• 882679-40-5 methyl 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate 
• 943319-70-8 ponatinib 
• 1232836-25-7 Ponatinib Hydrochloride 

Relevant articles and documents

Design, Synthesis, and in vitro Evaluation of P2X7 Antagonists

The P2X7 receptor is a promising target for the treatment of various diseases due to its significant role in inflammation and immune cell signaling. This work describes the design, synthesis, and in vitro evaluation of a series of novel derivatives bearing diverse scaffolds as potent P2X7 antagonists. Our approach was based on structural modifications of reported (adamantan-1-yl)methylbenzamides able to inhibit the receptor activation. The adamantane moieties and the amide bond were replaced, and the replacements were evaluated by a ligand-based pharmacophore model. The antagonistic potency of the synthesized analogues was assessed by two-electrode voltage clamp experiments, using Xenopus laevis oocytes that express the human P2X7 receptor. SAR studies suggested that the replacement of the adamantane ring by an aryl-cyclohexyl moiety afforded the most potent antagonists against the activation of the P2X7 cation channel, with analogue 2-chloro-N-[1-(3-(nitrooxymethyl)phenyl)cyclohexyl)methyl]benzamide (56) exhibiting the best potency with an IC50 value of 0.39 μΜ.

COMPOUNDS USEFUL FOR INHIBITING RAF DIMERS

The disclosure provides compounds of Formula I (Formula I) (c) And the pharmaceutically acceptable salts thereof. The A, B, C, and D rings and the variables, RA, RB, RC, RD, L0, L1, L2

KINASE INHIBITORS AND USES THEREOF

This invention described herein relates to compounds of general formula (I) : (I), in which variable groups are as defined herein, and to their preparation and use. Uses for the compounds and for compositions containing them include treatment of cancer and other diseases mediated by protein kinases, such as Bcr-Abl kinase, and mutants thereof, such as the T315I mutant.

Design, Synthesis, and Biological Evaluation of 3-(Imidazo[1,2- a]pyrazin-3-ylethynyl)-4-isopropyl- N-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)benzamide as a Dual Inhibitor of Discoidin Domain Receptors 1 and 2

Discoidin-domain receptors 1 and 2 (DDR1 and DDR2) are new potential targets for anti-inflammatory-drug discovery. A series of heterocycloalkynylbenzimides were designed and optimized to coinhibit DDR1 and DDR2. One of the most promising compounds, 5n, ti

3-ACETYLENYL-PYRAZOLE-PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USES THEREOF

The present invention relates to the field of chemical and medicine, more particularly, 3-ethynylpyrazolopyrimidine derivatives and their preparation methods and uses. The invention provides a 3-ethynylpyrazolopyrimidine derivative, and the structure is shown in formula I. The present invention also provides preparation methods and use of 3-ethynylpyrazolopyrimidine derivatives, comprising the compounds and derivatives, and their pharmaceutical compositions for the use of the treatment and prevention of tumors.

BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOG PATHWAY MODULATORS

The invention provides a method for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-fu

HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS AND COMBINATIONS THEREOF

Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by disregulation of a fatty acid synthase pathway by the administration of such compounds and combinations of such compounds and other therapeutic agents.

HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS

Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by disregulation of a fatty acid synthase pathway by the administration of such compounds.

Electronically connected [n]helicenes: Synthesis and chiroptical properties of enantiomerically pure (E)-1,2-di([6]helicen-2-yl)ethenes

We synthesized stilbenoid (E)-(P,P)- and (E)-(M,M)-[6]helicene dimers in enantiomerically pure form as part of a program aimed at the exploration of new strategies for the synthesis of large helicenes. The [2+2+2] cyclotrimerization of suitable triynes, r

New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives

This invention is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I), to pharmaceutical compositions comprising them, and to their use in therapy.